A Phase 3 interventional study of sitagliptin phosphate (+) metformin hydrochloride and metformin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-06-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 28th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,246 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 8th largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 86 in phase 3, and was the 23rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy and safety of an investigational treatment for type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Arm 1: drug
Drug: sitagliptin phosphate (+) metformin hydrochloride
Arm 2: active comparator
Drug: metformin
Drug pages: Sitagliptin · Metformin
sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
Also known as: MK0431A, Janumet™
metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
Change From Baseline in Hemoglobin A1c (A1C) at Week 18
A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.
Time frame: Baseline and Week 18
Number of Patients With A1C < 7.0% at Week 18
Time frame: Week 18
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18
FPG is measured as mg/dL. Thus, this change from baseline reflects the Week 18 FPG mg/dL minus the Week 0 FPG mg/dL.
Time frame: Baseline and Week 18
Change From Baseline in A1C at Week 44
A1C is measured as percent. Thus, this change from baseline reflects the Week 44 A1C percent minus the Week 0 A1C percent.
Time frame: Baseline and Week 44
Number of Patients With A1C < 7.0% at Week 44
Time frame: Week 44
First Patient In: 26-Jun-2007; Last Patient Last Visit for end of study: 28-Apr-2009; Two-hundred four medical clinics in the United States (US) and 5 in Puerto Rico.
| Milestone | Sita/Met FDC | Metformin |
|---|---|---|
| Started | 626 | 624 |
| Completed phase a | 484 | 482 |
| Completed phase b | 409 | 406 |
| Completed | 409 | 406 |
| Not completed | 217 | 218 |
| Withdrew: Adverse event | 29 | 33 |
| Withdrew: Creatinine/creatinine clearance criteria | 0 | 2 |
| Withdrew: Hyperglycemia criteria | 7 | 5 |
| Withdrew: Lack of efficacy | 4 | 16 |
| Withdrew: Lost to follow-up | 86 | 66 |
| Withdrew: Physician decision | 10 | 7 |
| Withdrew: Pregnancy | 4 | 2 |
| Withdrew: Protocol violation | 10 | 18 |
| Withdrew: Withdrawal by subject | 67 | 69 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.
| Percent | Sita/Met FDC | Metformin |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (A1C) at Week 18 | -2.37 (-2.49 to -2.24) | -1.76 (-1.88 to -1.64) |
| Participants | Sita/Met FDC | Metformin |
|---|---|---|
| Patients with A1C <7.0% at Week 18 | 275 | 193 |
| Patients with A1C ≥7.0% at Week 18 | 284 | 371 |
FPG is measured as mg/dL. Thus, this change from baseline reflects the Week 18 FPG mg/dL minus the Week 0 FPG mg/dL.
| mg/dL | Sita/Met FDC | Metformin |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 | -69.4 (-74.1 to -64.6) | -53.7 (-58.4 to -48.9) |
A1C is measured as percent. Thus, this change from baseline reflects the Week 44 A1C percent minus the Week 0 A1C percent.
| Percent | Sita/Met FDC | Metformin |
|---|---|---|
| Change From Baseline in A1C at Week 44 | -2.25 (-2.38 to -2.12) | -1.77 (-1.89 to -1.64) |
| Participants | Sita/Met FDC | Metformin |
|---|---|---|
| Patients with A1C <7.0% at Week 44 | 258 | 173 |
| Patients with A1C ≥7.0% at Week 44 | 302 | 396 |
Collected over Week 0 through Week 44. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sita/Met FDC | — | 28/625 (4.5%) | 173/625 (27.7%) |
| Metformin | — | 38/621 (6.1%) | 185/621 (29.8%) |
| Event | Sita/Met FDC | Metformin |
|---|---|---|
| Any Cardiac DisordersCardiac disorders | 5/625 | 6/621 |
| Any Infections and InfestationsInfections and infestations | 6/625 | 6/621 |
| Any Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/625 | 5/621 |
| Any Nervous System DisordersNervous system disorders | 1/625 | 5/621 |
| Any Vascular DisordersVascular disorders | 2/625 | 4/621 |
| Coronary artery diseaseCardiac disorders | 1/625 | 3/621 |
| Any General Disorders and Administration site ConditionsGeneral disorders | 1/625 | 3/621 |
| Any Psychiatric DisordersPsychiatric disorders | 2/625 | 3/621 |
| Any Respiratory, Thoracic and Mediastinal DisordersRespiratory, thoracic and mediastinal disorders | 3/625 | 1/621 |
| Any Gastrointestinal DisordersGastrointestinal disorders | 2/625 | 2/621 |
| Event | Sita/Met FDC | Metformin |
|---|---|---|
| Any Gastrointestinal DisordersGastrointestinal disorders | 107/625 | 136/621 |
| DiarrhoeaGastrointestinal disorders | 86/625 | 112/621 |
| Any Infections and infestationsInfections and infestations | 62/625 | 57/621 |
| NauseaGastrointestinal disorders | 37/625 | 44/621 |
| Any Nervous system disordersNervous system disorders | 35/625 | 23/621 |
| HeadacheNervous system disorders | 35/625 | 23/621 |
| NasopharyngitisInfections and infestations | 33/625 | 26/621 |
| Upper respiratory tract infectionInfections and infestations | 30/625 | 31/621 |
| Age, Continuous(years) | Sita/Met FDC | Metformin | Total |
|---|---|---|---|
| Mean | 49.4 ± 10.5 | 50.0 ± 10.5 | 49.7 ± 10.5 |
| Sex: Female, Male(Participants) | Sita/Met FDC | Metformin | Total |
|---|---|---|---|
| Female | 272 | 266 | 538 |
| Male | 353 | 355 | 708 |
| Race/Ethnicity, Customized(Participants) | Sita/Met FDC | Metformin | Total |
|---|---|---|---|
| Asian | 17 | 24 | 41 |
| Black | 82 | 88 | 170 |
| White | 508 | 489 | 997 |
| Other | 18 | 20 | 38 |
| Hemoglobin A1c (A1C)(Percent) | Sita/Met FDC | Metformin | Total |
|---|---|---|---|
| Mean | 9.91 ± 1.83 | 9.83 ± 1.77 | 9.87 ± 1.80 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jun 2007 to primary completion in Nov 2008, 16 months.
Results were first posted in Mar 2010, 1 year 4 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin